COMMUNIQUÉ DE PRESSE publié le 04/01/2024 à 12:30, il y a 8 mois 15 jours NanoViricides to Present at the Biotech Showcase in San Fransisco NanoViricides, Inc., a leader in antiviral therapies based on nanomedicines technology, is set to present at the Biotech Showcase™ 2024 in San Francisco. The presentation will include an update on the successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies, which contain the novel antiviral nanomachine NV-387. The company's President will discuss how NV-387 addresses the unmet need for a broad-spectrum antiviral drug as well as its potential across multiple virus families. With its wide spectrum of antiviral activity, NV-387 has the potential to revolutionize antiviral treatment, much like antibiotics did for bacterial infections. NanoViricides Antiviral Therapies NV-387 Biotech Showcase 2024 Broad-spectrum Antiviral Drug
COMMUNIQUÉ DE PRESSE publié le 28/11/2023 à 12:40, il y a 9 mois 21 jours The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 15/11/2023 à 12:45, il y a 10 mois 4 jours NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
COMMUNIQUÉ DE PRESSE publié le 14/11/2023 à 12:45, il y a 10 mois 5 jours Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
COMMUNIQUÉ DE PRESSE publié le 16/10/2023 à 12:45, il y a 11 mois 3 jours NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
COMMUNIQUÉ DE PRESSE publié le 12/10/2023 à 12:45, il y a 11 mois 7 jours NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
COMMUNIQUÉ DE PRESSE publié le 21/08/2023 à 12:45, il y a 1 année The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 11/07/2023 à 12:45, il y a 1 année 2 mois Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 06/07/2023 à 12:45, il y a 1 année 2 mois Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
COMMUNIQUÉ DE PRESSE publié le 29/06/2023 à 12:45, il y a 1 année 2 mois NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
Publié le 19/09/2024 à 17:45, il y a 10 heures 52 minutes Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Publié le 19/09/2024 à 17:45, il y a 10 heures 52 minutes Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Publié le 19/09/2024 à 17:45, il y a 10 heures 52 minutes Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Publié le 20/09/2024 à 02:00, il y a 2 heures 37 minutes Academy of Math and Science Celebrates Hispanic Heritage Month
Publié le 19/09/2024 à 23:15, il y a 5 heures 22 minutes Cypher Metaverse Inc. Announces Second Closing of Financing
Publié le 19/09/2024 à 23:00, il y a 5 heures 37 minutes WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Publié le 19/09/2024 à 23:00, il y a 5 heures 37 minutes Cerrado Files NI 43-101 Preliminary Economic Assessment Technical Report and Mineral Resource Estimate for The Minera Don Nicolas Mine in Santa Cruz, Argentina
Publié le 19/09/2024 à 21:09, il y a 7 heures 27 minutes EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Publié le 19/09/2024 à 18:44, il y a 9 heures 53 minutes Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 19/09/2024 à 18:03, il y a 10 heures 34 minutes Funding Circle Plc: POS-Transaction in Own Shares
Publié le 19/09/2024 à 17:52, il y a 10 heures 44 minutes PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Publié le 19/09/2024 à 17:52, il y a 10 heures 44 minutes PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros